You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
McKesson
Baxter
Medtronic
Dow

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

CASPOFUNGIN ACETATE Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which patents cover Caspofungin Acetate, and when can generic versions of Caspofungin Acetate launch?

Caspofungin Acetate is a drug marketed by Cipla, Fresenius Kabi Usa, Gland Pharma Ltd, Jiangsu Hengrui Med, Mylan Labs Ltd, and Xellia Pharms Aps. and is included in six NDAs. There is one patent protecting this drug.

This drug has fourteen patent family members in fourteen countries.

The generic ingredient in CASPOFUNGIN ACETATE is caspofungin acetate. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the caspofungin acetate profile page.

US ANDA Litigation and Generic Entry Outlook for Caspofungin Acetate

A generic version of CASPOFUNGIN ACETATE was approved as caspofungin acetate by FRESENIUS KABI USA on December 30th, 2016.

  Start Trial

Drug patent expirations by year for CASPOFUNGIN ACETATE
Drug Prices for CASPOFUNGIN ACETATE

See drug prices for CASPOFUNGIN ACETATE

Recent Clinical Trials for CASPOFUNGIN ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
European Organisation for Research and Treatment of Cancer - EORTCPhase 3
Children's Oncology GroupPhase 3
Merck Sharp & Dohme Corp.Phase 3

See all CASPOFUNGIN ACETATE clinical trials

Recent Litigation for CASPOFUNGIN ACETATE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Merck Sharp & Dohme Corp. v. Xellia Pharmaceuticals ApS2014-02-14
MERCK & CO, INC. v. SANDOZ INC.2010-05-06
MERCK & CO., INC. v. SANDOZ INC.2010-03-30

See all CASPOFUNGIN ACETATE litigation

Pharmacology for CASPOFUNGIN ACETATE
Synonyms for CASPOFUNGIN ACETATE
1-((4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)pneumocandin B0, diacetate (salt)
1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0 diacetate
1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
1)-peptide diacetate salt
179463-17-3
463C173
AC-27763
AKOS025401982
AKOS026750216
AOB3093
C52H88N10O15.2C2H4O2
C56H96N10O19
Cancidas
Cancidas (TN)
Caspofungin (Acetate)
Caspofungin acetate (JAN/USAN)
Caspofungin acetate [USAN:BAN:JAN]
Caspofungin Acetate [USAN]
caspofungin diacetate
CHEBI:59900
CS-0578
D02501
HY-17006
J-011452
L 743,872
L 743872
L-743,872
L-743872
LS-173700
MK 0991
MK-0991
MK0991
MolPort-029-887-122
MolPort-035-395-717
MolPort-044-561-291
OGUJBRYAAJYXQP-LLXMLGLCSA-N
Pneumocandin B0, 1-((4R,5S)-5-((2-aminoethyl)amino)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-((3R)-3-hydroxy-L-ornithine)-, diacetate (salt)
s3073
SCHEMBL149293
SW219088-1
UNII-VUW370O5QE
VUW370O5QE
W-5367
Y1176
Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE
Tradename Dosage Ingredient NDA Submissiondate
CANCIDAS POWDER;INTRAVENOUS caspofungin acetate 021227 2009-06-26

US Patents and Regulatory Information for CASPOFUNGIN ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cipla CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 209489-001 Jul 12, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Jiangsu Hengrui Med CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 200833-001 Jun 28, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 206110-002 Dec 30, 2016 AP RX No No   Start Trial   Start Trial Y   Start Trial
Xellia Pharms Aps CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 205923-002 Jul 2, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Jiangsu Hengrui Med CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 200833-002 Jun 28, 2018 AP RX No No   Start Trial   Start Trial   Start Trial
Cipla CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 209489-002 Jul 12, 2018 DISCN No No   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa CASPOFUNGIN ACETATE caspofungin acetate POWDER;INTRAVENOUS 206110-001 Dec 30, 2016 AP RX No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CASPOFUNGIN ACETATE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0620232 01C0054 France   Start Trial PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024
0620232 C300076 Netherlands   Start Trial PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232 SPC/GB02/002 United Kingdom   Start Trial A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232 2001/029 Ireland   Start Trial PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
0620232 44/2001 Austria   Start Trial PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
Baxter
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.